Skip to main content
OpenTrials
Completed

NCT Number: NCT02712853

Improving Autism Screening With Brain-Related miRNA

The goal of this project is to identify specific miRNAs that are increased or decreased in the saliva of children with developmental delay and are useful for screening toddlers for ASD. Such a screening tool would improve the specificity of diagnosis, streamline referrals to developmental specialists, and expedite the arrangement of early intervention services.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 month–6 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Penn State Milton S. Hershey Medical Center

Hershey, Pennsylvania, 17033, United States

About this study

The central aim of this project is to characterize the expression of exosomal microRNA (miRNA) in children with autism spectrum disorder (ASD). Currently, the CDC estimates the prevalence of ASD in U.S. children to be 1 in 68. Yet, the biological causes, diagnosis, and treatment of this disease remain ambiguous. Growing evidence implicates a genetic role in ASD. miRNAs regulate genetic expression and are altered in lymphocytes, neurons and serum of patients with ASD. Recent studies of miRNAs have shown that they can be packaged into exosomal vessels and extruded from neurons as extracellular signaling tools. This knowledge provides a novel approach for examining the genetic regulation of the central nervous system.

We propose to measure the expression of extracellular miRNA in children with ASD. Expression levels of miRNA from blood and saliva will be compared between children with autism and normally developing controls. The goal of this study will be to identify genetic regulatory mechanisms involved in ASD and provide potential biomarkers for diagnostic screening.

The primary endpoints of this study are as follows:

  • Characterization of brain-related miRNA in the saliva of children with ASD and typically developing control children between the ages of two and five years.
  • Identification of sets of miRNAs in saliva and plasma that are predictive of both ASD diagnosis and severity of ASD symptoms. This aim will enroll ASD and control children age 12-24 months (inclusive).

Secondary endpoints include the identification of miRNA expression patterns that correlate with ASD symptom severity measured with standardized neuropsychologic testing and to characterize parental knowledge and attitudes towards epigenetic testing in the context of ASD..

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • • Age at enrollment: 18 months and 6 years (inclusive)
  • Control group documented negative ASD screening on M-CHAT-R
  • ASD group: established DSM-5 diagnosis
  • Parent/guardian must be fluent in written and spoken English (required to complete study specific questionnaires etc)

Exclusion criteria

For autistic subjects study exclusion criteria will include:

  • Autistic subjects with known syndromic autism (attributed to a known genetic mutation)

Control subjects only exclusion criteria will include:

  • A diagnosis of autism

For both groups: wards of the state, active periodontal infection, active upper respiratory infection

Treatment and study plan

Saliva Collection

Other

Collection of saliva via swab for miRNA processing

Vineland Adaptive Behavior Scale-II Assessment

Other

Primary outcomes

  1. salivary miRNA profile

    Time frame: at time of collection (between 18 months and 6 years of age)

    Measures of miRNA abundance in saliva

Secondary outcomes

  1. Measures of adaptive function

    Time frame: at time of enrollment (between 18 months and 6 years)

    Vineland adaptive behavior composite score

  2. Measure of autistic behavior

    Time frame: at time of enrollment (between 18 months and 6 years)

    Autism Diagnostic Observation Schedule (ADOS) Composite Score (when clinically indicated)

Sponsors and collaborators

Lead sponsor

Milton S. Hershey Medical Center

Other

Registry information

Important dates

Study start
2015
Primary completion
2018
Study completion
2018
First posted
Mar 18, 2016
Registry last updated
Aug 22, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.